临床外科杂志 ›› 2023, Vol. 31 ›› Issue (4): 394-397.doi: 10.3969/j.issn.1005-6483.2023.04.026

• 综述与讲座 • 上一篇    下一篇

胆管癌靶向治疗进展

  

  1. 430030 武汉,华中科技大学同济医学院附属同济医院肝脏外科中心
  • 收稿日期:2022-04-11 接受日期:2022-04-11 出版日期:2023-04-25 发布日期:2023-04-25
  • 通讯作者: 董汉华,Email:hanhua_dong@hotmail.com
  • 基金资助:
    恒瑞肝胆胰恶性肿瘤研究基金青年研究基金项目(CXPJJH11800001-2018310)

Recent advances in targeted therapy for cholangiocarcinoma

  1. Hepatic Surgery Center,Tongji Hospital,Tongji Medical College Huazhong University of Science and Technology,Wuhan 430030, China
  • Received:2022-04-11 Accepted:2022-04-11 Online:2023-04-25 Published:2023-04-25

摘要: 胆管癌是源于胆管上皮的恶性肿瘤,其发病率逐年增加,特别是起源于肝内二级以上胆管分支的肝内胆管癌。早期症状隐匿,有效的筛查手段匮乏,大多数病人就诊时已失去根治性手术机会。随着对胆管癌基因组的检测,开发出几种可靶向基因改变的药物。具有临床意义活性的分子靶点主要包括成纤维细胞生长因子受体(FGFR)、异柠檬酸脱氢酶(IDH)、RAS-RAF-MEK-ERK、ERBB、VEGF和NTRK等。针对其靶点的药物作为二线治疗显示出较好的反应率和生存数据,特异性高、毒性小。靶向治疗渐渐在胆管癌治疗中崭露头角。

关键词: 胆管癌, 靶向治疗, 药物治疗

Abstract: Cholangiocarcinoma is a malignant tumor originating from the epithelium of the bile ducts,and its incidence is increasing year by year,especially intrahepatic bile duct carcinoma that originates from the bile duct branches above the second level in the liver.Due to the insidious early symptoms and the lack of effective screening methods,most patients have lost the opportunity for radical surgery by the time they present.Over the past few years,several drugs have been developed that target genetic alterations with the detection of the cholangiocarcinoma genome.The molecular targets with clinical significance mainly include fibroblast growth factor receptor(FGFR),isocitric acid dehydrogenase(IDH),RAS-RAF-MEK-ERK,ERBB,VEGF and NTRK.Drugs targeting their targets show encouraging response rates and survival data as second-line therapies,and are characterized by high specificity and low toxicity.Therefore,targeted therapy is gradually emerging in the treatment of cholangiocarcinoma.In this review,we discuss the latest advances in targeted therapies for cholangiocarcinoma.

Key words: cholangiocarcinoma, targeted therapy, medical treatment

[1] 陈健 朱余明. 非小细胞肺癌术后辅助治疗研究进展[J]. 临床外科杂志, 2022, 30(8): 707-713.
[2] 袁童 黄志勇. 肝癌免疫治疗4.0[J]. 临床外科杂志, 2022, 30(5): 490-493.
[3] 李秋梨 田佳禾 郭朱明. 复发或晚期甲状腺髓样癌的靶向治[J]. 临床外科杂志, 2022, 30(3): 287-289.
[4] 程立冬 刘京典 舒凯. 胶质瘤分子靶向治疗进展[J]. 临床外科杂志, 2022, 30(10): 998-1000.
[5] 梁宾勇 黄志勇 陈孝平. 新开发药物的临床应用对肝癌外科治疗决策的影响[J]. 临床外科杂志, 2021, 29(11): 1001-1003.
[6] 冯浩洁 姚颐 耿庆. 美国国家综合癌症网络临床实践指南:非小细胞肺癌(2021V1)更新解读[J]. 临床外科杂志, 2021, 29(1): 25-28.
[7] 李一鸣 邱红. 晚期胆道系统恶性肿瘤的化疗及靶向治疗药物进展[J]. 临床外科杂志, 2020, 28(8): 793-797.
[8] 罗定远 欧阳能太. 甲状腺癌分子诊断的现状与展望[J]. 临床外科杂志, 2020, 28(3): 285-288.
[9] 李晓, 蔡琳, 张勇等. 西北地区单中心汉族人群食管鳞癌病人基因分布状况研究[J]. 临床外科杂志, 2019, 27(7): 571-573.
[10] 王璇, 张昊, 党诚学. 食管胃结合部肿瘤的治疗[J]. 临床外科杂志, 2019, 27(5): 446-448.
[11] 虞伟星 沈周俊. 环氧合酶-2在膀胱癌中的表达及临床意义[J]. 临床外科杂志, 2011, 19(10): 694-694.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 邱江. 心脏死亡捐献供肾移植免疫抑制方案的选择[J]. 临床外科杂志, 2016, 24(10): 735 .
[2] 石宇;刘学刚 . 冠状动脉旁路移植术后短期内应用强化他汀对患者出血风险的研究[J]. 临床外科杂志, 2016, 24(10): 750 .
[3] 阿布力克木·毛拉尤甫;郑秉礼. 胰腺实性假乳头状瘤45例手术治疗分析[J]. 临床外科杂志, 2016, 24(10): 764 .
[4] 李义亮;张成;克力木;等. 完全腹腔镜下远端胃癌根治术的临床体会[J]. 临床外科杂志, 2016, 24(10): 769 .
[5] 宋华;单若冰;张晋绥;等. 产前超声诊断对新生儿消化道梗阻性疾病手术治疗价值的观察[J]. 临床外科杂志, 2016, 24(10): 780 .
[6] 陈绍站;许勇;李婧;等. 防旋股骨近端髓内针与股骨近端解剖锁定钢板治疗转子间骨折的疗效比较[J]. 临床外科杂志, 2016, 24(10): 787 .
[7] 戴强;徐康;周治军;等. 湖北天门地区泌尿系结石成分及特征分析[J]. 临床外科杂志, 2016, 24(10): 789 .
[8] 刘琼;江辉. 喉罩在小儿舌系带矫正手术中的应用[J]. 临床外科杂志, 2016, 24(10): 792 .
[9] 胡光俊;宋晓阳;陶军. 右美托咪定添加到罗哌卡因中对腰丛坐骨神经阻滞及镇静的影响[J]. 临床外科杂志, 2016, 24(10): 796 .
[10] 周观金;彭昊;陈森. 全膝关节置换治疗膝关节炎术后早期镇痛的研究进展[J]. 临床外科杂志, 2016, 24(10): 804 .